Plasmodium falciparum aminopeptidase N (PfA-M1)

Plasmodium falciparum aminopeptidase N (PfA-M1) is a zinc-dependent metalloenzyme that is essential for the survival and development of the malaria parasite during its symptomatic blood stage (UniProt: Q8I6V6). It plays a pivotal role in the final steps of the hemoglobin degradation pathway, where it hydrolyzes short peptides into free amino acids (PubMed: 20876113). These amino acids are critical for the parasite's protein synthesis and for maintaining osmotic balance within the host erythrocyte. Inhibition of PfA-M1 leads to the accumulation of undigested peptides and results in parasite starvation and death (PubMed: 25664371). As a therapeutic target, PfA-M1 is highly attractive because its active site possesses distinct structural features that allow for the design of selective inhibitors, minimizing cross-reactivity with human aminopeptidases like CD13 or ERAP1 (PubMed: 22403578). Current drug discovery efforts focus on small-molecule inhibitors such as bestatin and hydroxamate-based compounds that bind to the catalytic zinc ion.

Other names

M1-family alanyl aminopeptidasePfM1AAPPfM1Aminopeptidase NAlanyl aminopeptidase

Inhibition of the zinc-dependent catalytic activity of the enzyme, which prevents the hydrolysis of hemoglobin-derived peptides into free amino acids, thereby starving the parasite and disrupting osmotic balance (PubMed: 20876113, 25664371).